International Hippocrates Congress on Medical and Health Sciences, Ankara, Turkey, 1 - 03 March 2019, pp.387-403
82-PRESENTATION TYPE: Oral Presentation
This study was conducted to analyze the influence of oral therapy with Atorvastatin in Streptozotocin (STZ) -induced diabetic rats. Although there are studies that could not verify Atorvastatin's influence on glycemic balance, many others in humans and animals has shown that Atorvastatin may have a significant effect on insulin resistance but until now we don’t have evidences about the molecular mechanism used for this process. At the same time the purpose of this research is to see if Atorvastatin will have an impact on insulin sensitivity, lipometabolism and the association that can exist between TG/HDL-C ratio and IR. To come to this conclusion we have followed the various biochemical parameters such as: fasting blood glucose levels; determination of Insulin level and HOMA-IR; triglycerides; high-density lipoprotein (HDL), cholesterol and TG/HDL-C ratio in diabetic and healthy rats.
Thus, rats were induced with Streptozotocin (STZ), and diabetic rats were administered with Atorvastatin (A) (10 and 20 mg/kg/d) consecutively for 3 weeks. The effects of Atorvastatin on body weight, levels of blood glucose and lipometabolism were monitored by routine measurement and biochemical assays. As we have expected, we have a drastic increase in glucose in the diabetes group associated with decreased body weight but Atorvastatin elevated the body weight of diabetic rats (P<0.01), there was a reduce of blood glucose levels (P<0.01), an increase of the levels of insulin and high-density lipoprotein cholesterol (HDL-C) in plasma<(P<0.05), and impaired HOMA-IR and TG/HDL-C ratio. We think that the
diabetogenic effect of Atorvastatin is related to insulin resistance and TG/HDL ratio is not
a good marker of IR in the assessment of diabetes.
Keywords: Atorvastatin; Streptozotocin; Blood Glucose; Rats; Insulin; Triglycerides.